Author: Lucy Jean Sannes, Ph.D., M.B.A
Combination Drug/Diagnostics: Fueling Growth of Personalized Medicine details the commercial successes of an future pharmacological therapies and diagnostic test combination products.
Key topics covered include:
- Successful Rx/Dx products on the market
- Opportunities for future/drug diagnostic combinations
- Emerging new applications
- Strategic options for pharmaceutical and diagnostic companies
- Regulatory and reimbursement issues
- Physician education and acceptable hurdles
- Interviews with experts
Combination Drug/Diagnostics: Fueling Growth of Personalized Medicine examines the role of Rx/Dx products in cancer treatment and a variety of other disease indications. More than fifteen tables in this report summarize the broad activity in this product field. As examples of drug/diagnostic combinations succeed in the market, interest in this field continues to grow and offers promising opportunities for novel products. This report provides a comprehensive look at all available combination therapeutic and diagnostic products from regulatory required co-marketed products to label recommended combinations and identifies factors leading to market success.
The report emphasizes the market perspectives in the field. Nearly all major pharmaceutical companies have personalized medicine strategies in place. This report describes the activities of 104 pharmaceutical and diagnostic companies in the Rx/Dx space.
ABOUT THE AUTHOR
Lucy J. Sannes, PhD, MBA, is president of Sannes & Associates, a consulting firm specializing in evaluation and management of the biosciences. Before forming Sannes & Associates, she held management positions at Genetic Systems and Abbott Laboratories in product development, product support, and technical marketing. Dr. Sannes received her PhD in biological chemistry from the University of Michigan and her MBA from Seattle